Related Experiment Video

Updated: Jun 13, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma

Kate Gerster1, Wei Shi, Benjamin Ng

  • 1Division of Applied Molecular Oncology, Ontario Cancer Institute, Toronto, ON, Canada.

International Journal of Radiation Oncology, Biology, Physics
|April 17, 2010
PubMed
Abstract

Insights

Targeting polo-like kinase 1 (Plk1) with siRNA combined with radiotherapy shows promise for head-and-neck squamous cell carcinoma (HNSCC). Plk1 depletion enhanced cancer cell death and inhibited tumor growth, especially when combined with radiation therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Head-and-neck squamous cell carcinoma (HNSCC) remains a significant health challenge.
  • Identifying novel therapeutic targets is crucial for improving HNSCC treatment outcomes.

Purpose of the Study:

  • To evaluate the efficacy of targeting polo-like kinase 1 (Plk1) in combination with ionizing radiotherapy (RT) for HNSCC.
  • To assess the therapeutic potential of Plk1 inhibition in preclinical models of HNSCC.

Main Methods:

  • Small interfering RNA (siRNA) targeting Plk1 (siPlk1) was used to reduce Plk1 mRNA and protein levels in FaDu HNSCC cells.
  • Cellular effects, including cytotoxicity, apoptosis, and cell cycle arrest, were assessed using various assays.
  • In vivo efficacy was evaluated in mouse xenograft models.

Main Results:

  • siPlk1 significantly reduced Plk1 expression and increased markers of cytotoxicity and apoptosis in HNSCC cells.
  • The combination of siPlk1 and RT demonstrated enhanced anti-cancer effects compared to either treatment alone.
  • siPlk1 treatment delayed tumor formation and inhibited tumor growth in vivo, with augmented effects when combined with RT.

Conclusions:

  • Plk1 is a viable therapeutic target for HNSCC, as its depletion induces significant cytotoxicity and reduces tumor-forming potential.
  • Plk1 inhibition acts as a potent radiation sensitizer, enhancing the efficacy of radiotherapy in HNSCC treatment.

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...